{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:44:28Z","timestamp":1792032268766,"version":"4.4.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"DOI":"10.1007\/s40121-026-01455-9","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:53:42Z","timestamp":1792029222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and Characterization of Patient Populations at High Risk for Clostridioides difficile Infection (CDI): A Narrative Review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-1024","authenticated-orcid":false,"given":"Jessica R.","family":"Allegretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3779-2796","authenticated-orcid":false,"given":"Erik R.","family":"Dubberke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1tia","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3013-3843","authenticated-orcid":false,"given":"Christian John","family":"Lillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-2868","authenticated-orcid":false,"given":"Mark H.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"7","key":"1455_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","volume":"38","author":"J Czepiel","year":"2019","unstructured":"Czepiel J, Drozdz M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211\u201321. https:\/\/doi.org\/10.1007\/s10096-019-03539-6.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"1455_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.53854\/liim-3203-3","volume":"32","author":"F Salvati","year":"2024","unstructured":"Salvati F, Catania F, Murri R, Fantoni M, Torti C. Clostridioides difficile infection: an update. Infez Med. 2024;32(3):280\u201391. https:\/\/doi.org\/10.53854\/liim-3203-3.","journal-title":"Infez Med"},{"key":"1455_CR3","doi-asserted-by":"publisher","first-page":"16020","DOI":"10.1038\/nrdp.2016.20","volume":"2","author":"WK Smits","year":"2016","unstructured":"Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. https:\/\/doi.org\/10.1038\/nrdp.2016.20.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1455_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/idr17020031","volume":"17","author":"RAA Akorful","year":"2025","unstructured":"Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The global burden of Clostridioides difficile infections, 2016-2024: a systematic review and meta-analysis. Infect Dis Rep. 2025;17(2):31. https:\/\/doi.org\/10.3390\/idr17020031.","journal-title":"Infect Dis Rep"},{"key":"1455_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2024.102878","volume":"88","author":"FJ Angulo","year":"2024","unstructured":"Angulo FJ, Furtado M, Gonzalez E, Zhang P, Kelly PH, Moisi JC. Incidence of public health surveillance-reported Clostridioides difficile infections in thirteen countries worldwide: a narrative review. Anaerobe. 2024;88:102878. https:\/\/doi.org\/10.1016\/j.anaerobe.2024.102878.","journal-title":"Anaerobe"},{"key":"1455_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211016248","volume":"14","author":"Y Fu","year":"2021","unstructured":"Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Ther Adv Gastroenterol. 2021;14:17562848211016248. https:\/\/doi.org\/10.1177\/17562848211016248.","journal-title":"Ther Adv Gastroenterol"},{"issue":"14","key":"1455_CR7","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1910215.","journal-title":"N Engl J Med"},{"issue":"10","key":"1455_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14149","volume":"2","author":"NA Turner","year":"2019","unstructured":"Turner NA, Grambow SC, Woods CW, Fowler VG Jr, Moehring RW, Anderson DJ, et al. Epidemiologic trends in Clostridioides difficile infections in a regional community hospital network. JAMA Netw Open. 2019;2(10):e1914149. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.14149.","journal-title":"JAMA Netw Open"},{"issue":"18","key":"1455_CR9","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","volume":"379","author":"SS Magill","year":"2018","unstructured":"Magill SS, O\u2019Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care-associated infections in US hospitals. N Engl J Med. 2018;379(18):1732\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1801550.","journal-title":"N Engl J Med"},{"issue":"1","key":"1455_CR10","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010407","volume":"9","author":"E Balsells","year":"2019","unstructured":"Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407. https:\/\/doi.org\/10.7189\/jogh.09.010407.","journal-title":"J Glob Health"},{"key":"1455_CR11","doi-asserted-by":"publisher","first-page":"175628482110327","DOI":"10.1177\/17562848211032797","volume":"14","author":"K Fettucciari","year":"2021","unstructured":"Fettucciari K, Marconi P, Marchegiani A, Fruganti A, Spaterna A, Bassotti G. Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile. Ther Adv Gastroenterol. 2021;14:17562848211032796. https:\/\/doi.org\/10.1177\/17562848211032797.","journal-title":"Ther Adv Gastroenterol"},{"issue":"4","key":"1455_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/microorganisms11040845","volume":"11","author":"R Markovska","year":"2023","unstructured":"Markovska R, Dimitrov G, Gergova R, Boyanova L. Clostridioides difficile, a new \u201csuperbug.\u201d Microorganisms. 2023;11(4):845. https:\/\/doi.org\/10.3390\/microorganisms11040845.","journal-title":"Microorganisms"},{"issue":"7","key":"1455_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071141","volume":"12","author":"C Liu","year":"2023","unstructured":"Liu C, Monaghan T, Yadegar A, Louie T, Kao D. Insights into the evolving epidemiology of Clostridioides difficile infection and treatment: a global perspective. Antibiotics (Basel). 2023;12(7):1141. https:\/\/doi.org\/10.3390\/antibiotics12071141.","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"1455_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13080646","volume":"13","author":"P Spigaglia","year":"2024","unstructured":"Spigaglia P. Clostridioides difficile and gut microbiota: from colonization to infection and treatment. Pathogens (Basel). 2024;13(8):646. https:\/\/doi.org\/10.3390\/pathogens13080646.","journal-title":"Pathogens (Basel)"},{"issue":"3","key":"1455_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae085","volume":"11","author":"CN Abou Chakra","year":"2024","unstructured":"Abou Chakra CN, Gagnon A, Lapointe S, Granger MF, Levesque S, Valiquette L. The strain and the clinical outcome of Clostridioides difficile infection: a meta-analysis. Open Forum Infect Dis. 2024;11(3):ofae085. https:\/\/doi.org\/10.1093\/ofid\/ofae085.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1455_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13020118","volume":"13","author":"JE Markantonis","year":"2024","unstructured":"Markantonis JE, Fallon JT, Madan R, Alam MZ. Clostridioides difficile infection: diagnosis and treatment challenges. Pathogens (Basel). 2024;13(2):118. https:\/\/doi.org\/10.3390\/pathogens13020118.","journal-title":"Pathogens (Basel)"},{"key":"1455_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2025.102953","volume":"93","author":"JJ Vernon","year":"2025","unstructured":"Vernon JJ, Eyre DW, Wilcox MH, Freeman J. Molecular clock complexities of Clostridioides difficile. Anaerobe. 2025;93:102953. https:\/\/doi.org\/10.1016\/j.anaerobe.2025.102953.","journal-title":"Anaerobe"},{"issue":"1","key":"1455_CR18","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2022.2","volume":"2","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Nelson WW, Teigland C, Dahdal DN. Clinical burden of recurrent Clostridioides difficile infection in the medicare population: a real-world claims analysis. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e60. https:\/\/doi.org\/10.1017\/ash.2022.2.","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"1455_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijid.2024.01.002","volume":"140","author":"S Ghosh","year":"2015","unstructured":"Ghosh S, Antunes A, Rinta-Kokko H, Chaparova E, Lay-Flurrie S, Tricotel A, et al. Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: the RECUR England study. Int J Infect Dis. 2015;140:31\u20138. https:\/\/doi.org\/10.1016\/j.ijid.2024.01.002.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"1455_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae127","volume":"11","author":"AY Guh","year":"2024","unstructured":"Guh AY, Li R, Korhonen L, Winston LG, Parker E, Czaja CA, et al. Characteristics of patients with initial Clostridioides difficile infection (CDI) that are associated with increased risk of multiple CDI recurrences. Open Forum Infect Dis. 2024;11(4):ofae127. https:\/\/doi.org\/10.1093\/ofid\/ofae127.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 6","key":"1455_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/1469-0691.12046","volume":"18","author":"CP Kelly","year":"2012","unstructured":"Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(Suppl 6):21\u20137. https:\/\/doi.org\/10.1111\/1469-0691.12046.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1455_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5009\/gnl18071","volume":"13","author":"JH Song","year":"2019","unstructured":"Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16\u201324. https:\/\/doi.org\/10.5009\/gnl18071.","journal-title":"Gut Liver"},{"issue":"1","key":"1455_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","volume":"23","author":"P Feuerstadt","year":"2023","unstructured":"Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(1):132. https:\/\/doi.org\/10.1186\/s12879-023-08096-0.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"1455_CR24","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s40121-023-00833-x","volume":"12","author":"EP Armstrong","year":"2023","unstructured":"Armstrong EP, Malone DC, Franic DM, Pham SV, Gratie D, Amin A. Patient experiences with Clostridioides difficile infection and its treatment: a systematic literature review. Infect Dis Ther. 2023;12(7):1775\u201395. https:\/\/doi.org\/10.1007\/s40121-023-00833-x.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1455_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41687-020-0179-1","volume":"4","author":"L Lurienne","year":"2020","unstructured":"Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes. 2020;4(1):14. https:\/\/doi.org\/10.1186\/s41687-020-0179-1.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"1455_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40271-013-0043-y","volume":"7","author":"I Guillemin","year":"2014","unstructured":"Guillemin I, Marrel A, Lambert J, Beriot-Mathiot A, Doucet C, Kazoglou O, et al. Patients\u2019 experience and perception of hospital-treated Clostridium difficile\u00a0infections: a qualitative study. Patient. 2014;7(1):97\u2013105. https:\/\/doi.org\/10.1007\/s40271-013-0043-y.","journal-title":"Patient"},{"key":"1455_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1610-3","volume":"16","author":"K Desai","year":"2016","unstructured":"Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis. 2016;16:303. https:\/\/doi.org\/10.1186\/s12879-016-1610-3.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1455_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jhin.2009.10.016","volume":"74","author":"SS Ghantoji","year":"2010","unstructured":"Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74(4):309\u201318. https:\/\/doi.org\/10.1016\/j.jhin.2009.10.016.","journal-title":"J Hosp Infect"},{"key":"1455_CR29","doi-asserted-by":"publisher","first-page":"175628482110186","DOI":"10.1177\/17562848211018654","volume":"14","author":"A Gupta","year":"2021","unstructured":"Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol. 2021;14:17562848211018654. https:\/\/doi.org\/10.1177\/17562848211018654.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"1455_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jhin.2020.07.019","volume":"106","author":"C Robertson","year":"2020","unstructured":"Robertson C, Pan J, Kavanagh K, Ford I, McCowan C, Bennie M, et al. Cost burden of Clostridioides difficile infection to the health service: a retrospective cohort study in Scotland. J Hosp Infect. 2020;106(3):554\u201361. https:\/\/doi.org\/10.1016\/j.jhin.2020.07.019.","journal-title":"J Hosp Infect"},{"issue":"2","key":"1455_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14740\/gr1371","volume":"14","author":"D Solanki","year":"2017","unstructured":"Solanki D, Kichloo A, El-Amir Z, Dahiya DS, Singh J, Wani F, et al. Clostridium difficile infection hospitalizations in the United States: insights from the 2017 National Inpatient Sample. Gastroenterol Res. 2017;14(2):87\u201395. https:\/\/doi.org\/10.14740\/gr1371.","journal-title":"Gastroenterol Res"},{"issue":"8","key":"1455_CR32","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ajic.2019.01.007","volume":"47","author":"E Verheyen","year":"2019","unstructured":"Verheyen E, Dalapathi V, Arora S, Patel K, Mankal PK, Kumar V, et al. High 30-day readmission rates associated with Clostridium difficile infection. Am J Infect Control. 2019;47(8):922\u20137. https:\/\/doi.org\/10.1016\/j.ajic.2019.01.007.","journal-title":"Am J Infect Control"},{"issue":"2","key":"1455_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-0040-1701234","volume":"33","author":"NA Turner","year":"2020","unstructured":"Turner NA, Anderson DJ. Hospital infection control: Clostridioides difficile. Clin Colon Rectal Surg. 2020;33(2):98\u2013108. https:\/\/doi.org\/10.1055\/s-0040-1701234.","journal-title":"Clin Colon Rectal Surg"},{"issue":"2","key":"1455_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100991","volume":"6","author":"A Otu","year":"2025","unstructured":"Otu A, Chudasama D, Hope R, Jeyaratnam D. Data for action: the crucial role of hospitals in controlling Clostridioides difficile infection in England. Lancet Microbe. 2025;6(2):100991. https:\/\/doi.org\/10.1016\/j.lanmic.2024.100991.","journal-title":"Lancet Microbe"},{"issue":"10","key":"1455_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.32114","volume":"4","author":"M Alrawashdeh","year":"2021","unstructured":"Alrawashdeh M, Rhee C, Hsu H, Wang R, Horan K, Lee GM. Assessment of federal value-based incentive programs and in-hospital Clostridioides difficile infection rates. JAMA Netw Open. 2021;4(10):e2132114. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.32114.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1455_CR36","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/jac\/dkx005","volume":"72","author":"GB Scappaticci","year":"2017","unstructured":"Scappaticci GB, Perissinotti AJ, Nagel JL, Bixby DL, Marini BL. Risk factors and impact of Clostridium difficile recurrence on haematology patients. J Antimicrob Chemother. 2017;72(5):1488\u201395. https:\/\/doi.org\/10.1093\/jac\/dkx005.","journal-title":"J Antimicrob Chemother"},{"issue":"16","key":"1455_CR37","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMra1403772","volume":"372","author":"DA Leffler","year":"2015","unstructured":"Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539\u201348. https:\/\/doi.org\/10.1056\/NEJMra1403772.","journal-title":"N Engl J Med"},{"issue":"1","key":"1455_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/MOG.0000000000000989","volume":"40","author":"C Normington","year":"2024","unstructured":"Normington C, Chilton CH, Buckley AM. Clostridioides difficile infections; new treatments and future perspectives. Curr Opin Gastroenterol. 2024;40(1):7\u201313. https:\/\/doi.org\/10.1097\/MOG.0000000000000989.","journal-title":"Curr Opin Gastroenterol"},{"key":"1455_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-micro-091014-104115","volume":"69","author":"CM Theriot","year":"2015","unstructured":"Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol. 2015;69:445\u201361. https:\/\/doi.org\/10.1146\/annurev-micro-091014-104115.","journal-title":"Annu Rev Microbiol"},{"issue":"3","key":"1455_CR40","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jac\/dkr508","volume":"67","author":"MP Hensgens","year":"2012","unstructured":"Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742\u20138. https:\/\/doi.org\/10.1093\/jac\/dkr508.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1455_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad413","volume":"10","author":"AC Miller","year":"2023","unstructured":"Miller AC, Arakkal AT, Sewell DK, Segre AM, Tholany J, Polgreen PM. Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: a case-control study. Open Forum Infect Dis. 2023;10(8):ofad413. https:\/\/doi.org\/10.1093\/ofid\/ofad413.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1455_CR42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/jac\/dkw528","volume":"72","author":"K Kavanagh","year":"2017","unstructured":"Kavanagh K, Pan J, Marwick C, Davey P, Wiuff C, Bryson S, et al. Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case-control study using administrative data. J Antimicrob Chemother. 2017;72(4):1193\u2013201. https:\/\/doi.org\/10.1093\/jac\/dkw528.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1455_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00135-23","volume":"37","author":"S Di Bella","year":"2024","unstructured":"Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffre M, et al. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clin Microbiol Rev. 2024;37(2):e0013523. https:\/\/doi.org\/10.1128\/cmr.00135-23.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"1455_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cmi.2021.09.026","volume":"28","author":"TM van Rossen","year":"2022","unstructured":"van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls C, Dekkers OM, Kuijper EJ, Keller JJ, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect. 2022;28(3):321\u201331. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.026.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1455_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12879-017-2553-z","volume":"17","author":"A Delgado","year":"2017","unstructured":"Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals. BMC Infect Dis. 2017;17(1):448. https:\/\/doi.org\/10.1186\/s12879-017-2553-z.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"1455_CR46","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3201\/eid2509.181142","volume":"25","author":"M Kamboj","year":"2019","unstructured":"Kamboj M, Gennarelli RL, Brite J, Sepkowitz K, Lipitz-Snyderman A. Risk for Clostridiodes difficile infection among older adults with cancer. Emerg Infect Dis. 2019;25(9):1683\u20139. https:\/\/doi.org\/10.3201\/eid2509.181142.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"1455_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.6004\/jnccn.2017.0046","volume":"15","author":"A Gupta","year":"2017","unstructured":"Gupta A, Tariq R, Frank RD, Jean GW, Beg MS, Pardi DS, et al. Trends in the incidence and outcomes of hospitalized cancer patients with Clostridium difficile infection: a nationwide analysis. J Natl Compr Canc Netw. 2017;15(4):466\u201372. https:\/\/doi.org\/10.6004\/jnccn.2017.0046.","journal-title":"J Natl Compr Canc Netw"},{"key":"1455_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103371","volume":"87","author":"M Mikulska","year":"2025","unstructured":"Mikulska M, Robin C, Neofytos D, Oltolini C, Piekarska A, Reigadas E, et al. Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10). EClinicalMedicine. 2025;87:103371. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103371.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"1455_CR49","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1080\/17425247.2025.2556320","volume":"22","author":"P Zhang","year":"2025","unstructured":"Zhang P, Lin R, Gao J, Ouyang G. From stem cell transplantation to stem cell-based drug delivery systems targeting hematological malignancies: recent advances and clinical considerations. Expert Opin Drug Deliv. 2025;22(11):1751\u201368. https:\/\/doi.org\/10.1080\/17425247.2025.2556320.","journal-title":"Expert Opin Drug Deliv"},{"key":"1455_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.801475","volume":"12","author":"Y Luo","year":"2022","unstructured":"Luo Y, Zhang S, Shang H, Cui W, Wang Q, Zhu B. Prevalence of Clostridium difficile infection in the hematopoietic transplantation setting: update of systematic review and meta-analysis. Front Cell Infect Microbiol. 2022;12:801475. https:\/\/doi.org\/10.3389\/fcimb.2022.801475.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"1455_CR51","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.bbmt.2014.06.001","volume":"20","author":"IM Zacharioudakis","year":"2014","unstructured":"Zacharioudakis IM, Ziakas PD, Mylonakis E. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies. Biol Blood Marrow Transplant. 2014;20(10):1650\u20134. https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.001.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1455_CR52","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2024.90","volume":"4","author":"KM Reitmeyer","year":"2024","unstructured":"Reitmeyer KM, Rana B, Awad D, Huang E, Park JJ, Yassin A, et al. Effectiveness of oral vancomycin as prophylaxis against Clostridioides difficile infection in hematopoietic stem cell transplant patients. Antimicrob Steward Healthc Epidemiol. 2024;4(1):e107. https:\/\/doi.org\/10.1017\/ash.2024.90.","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"issue":"11","key":"1455_CR53","doi-asserted-by":"publisher","first-page":"ofae622","DOI":"10.1093\/ofid\/ofae622","volume":"11","author":"MJ Williams","year":"2024","unstructured":"Williams MJ, Atienza S, Franzen E, Rathod H, Mejaki B, Graff J, et al. Evaluation of primary oral vancomycin prophylaxis against Clostridioides difficile infection during autologous stem cell transplantation. Open Forum Infect Dis. 2024;11(11):ofae622. https:\/\/doi.org\/10.1093\/ofid\/ofae622.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1455_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70025","volume":"27","author":"B Fusco","year":"2025","unstructured":"Fusco B, Tomita-Barber J, Mazzaferro N, Tyno A, McEntee N, Greenberg P, et al. Prophylactic vancomycin in the primary prevention of Clostridium difficile in allogeneic stem cell transplant. Transpl Infect Dis. 2025;27(3):e70025. https:\/\/doi.org\/10.1111\/tid.70025.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"1455_CR55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3138\/jammi-2024-0032","volume":"10","author":"N Janusz","year":"2025","unstructured":"Janusz N, Mortimer L, Leite T, Carroll A, Kekre N, Kennah M, et al. Using routine asymptomatic Clostridioides difficile testing to identify patients at high risk of developing C. difficile infection during hematopoietic cell transplantation. J Assoc Med Microbiol Infect Dis Can. 2025;10(3):239\u201344. https:\/\/doi.org\/10.3138\/jammi-2024-0032.","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"issue":"1","key":"1455_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1017\/ice.2025.10330","volume":"47","author":"J O'Brien","year":"2026","unstructured":"O\u2019Brien J, Hamilton B, Pappas MA, Deshpande A. Clinical characteristics and risk factors for Clostridioides difficile infection in the hematopoietic cell transplantation population. Infect Control Hosp Epidemiol. 2026;47(1):25\u201335. https:\/\/doi.org\/10.1017\/ice.2025.10330.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"1455_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jtct.2022.02.013","volume":"28","author":"CD Alonso","year":"2022","unstructured":"Alonso CD, Maron G, Kamboj M, Carpenter PA, Gurunathan A, Mullane KM, et al. American Society for Transplantation and Cellular Therapy Series: #5-Management of Clostridioides difficile infection in hematopoietic cell transplant recipients. Transplant Cell Ther. 2022;28(5):225\u201332. https:\/\/doi.org\/10.1016\/j.jtct.2022.02.013.","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"1455_CR58","doi-asserted-by":"publisher","first-page":"471 e1","DOI":"10.1016\/j.jtct.2023.04.010","volume":"29","author":"CD Ford","year":"2023","unstructured":"Ford CD, Hoda D, Lopansri BK, Parra M, Sharma P, Asch J. An algorithm addressing the problem of overdiagnosis of Clostridioides difficile infections in hematopoietic stem cell transplantation recipients: effects on C. difficile infection rates and patient outcomes. Transplant Cell Ther. 2023;29(7):471 e1-e7. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.010.","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"1455_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13720","volume":"24","author":"KM Obeid","year":"2022","unstructured":"Obeid KM, Sapkota S, Cao Q, Richmond S, Watson AP, Karadag FK, et al. Early Clostridioides difficile infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients. Transpl Infect Dis. 2022;24(1):e13720. https:\/\/doi.org\/10.1111\/tid.13720.","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"1455_CR60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1017\/ice.2017.12","volume":"38","author":"NN Shah","year":"2017","unstructured":"Shah NN, McClellan W, Flowers CR, Lonial S, Khoury H, Waller EK, et al. Evaluating risk factors for Clostridium difficile infection in stem cell transplant recipients: a national study. Infect Control Hosp Epidemiol. 2017;38(6):651\u20137. https:\/\/doi.org\/10.1017\/ice.2017.12.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"1455_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12649","volume":"19","author":"SD Aldrete","year":"2017","unstructured":"Aldrete SD, Kraft CS, Magee MJ, Chan A, Hutcherson D, Langston AA, et al. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period. Transpl Infect Dis. 2017;19(1):e12649. https:\/\/doi.org\/10.1111\/tid.12649.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"1455_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/ipc.0000000000000798","volume":"28","author":"A Majeed","year":"2020","unstructured":"Majeed A, Larriva MM, Iftikhar A, Mushtaq A, Campbell P, Nadeem Malik M, et al. A single-center experience and literature review of management strategies for Clostridium difficile infection in hematopoietic stem cell transplant patients. Infect Dis Clin Pract (Baltim Md). 2020;28(1):10\u20135. https:\/\/doi.org\/10.1097\/ipc.0000000000000798.","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"issue":"4","key":"1455_CR63","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhin.2019.12.017","volume":"104","author":"L Duhalde","year":"2020","unstructured":"Duhalde L, Lurienne L, Wingen-Heimann SM, Guillou L, Buffet R, Bandinelli PA. Excess burden associated with Clostridioides difficile infection in haematological patients occurring during hospitalization with induction chemotherapy in the USA. J Hosp Infect. 2020;104(4):560\u20136. https:\/\/doi.org\/10.1016\/j.jhin.2019.12.017.","journal-title":"J Hosp Infect"},{"issue":"16_suppl","key":"1455_CR64","doi-asserted-by":"publisher","first-page":"e19054","DOI":"10.1200\/JCO.2022.40.16_suppl.e19054","volume":"40","author":"R Mahfouz","year":"2022","unstructured":"Mahfouz R, Mansour M, Obeidat AE, Darweesh M, Batayneh O, Ghous G. Outcomes of Clostridioides difficile infection in patients with hematopoietic stem cell transplant. J Clin Oncol. 2022;40(16_suppl):e19054. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e19054.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1455_CR65","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/infdis\/jix011","volume":"215","author":"YJ Lee","year":"2017","unstructured":"Lee YJ, Arguello ES, Jenq RR, Littmann E, Kim GJ, Miller LC, et al. Protective factors in the intestinal microbiome against Clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2017;215(7):1117\u201323. https:\/\/doi.org\/10.1093\/infdis\/jix011.","journal-title":"J Infect Dis"},{"issue":"4","key":"1455_CR66","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/phar.1914","volume":"37","author":"TL Scardina","year":"2017","unstructured":"Scardina TL, Kang Martinez E, Balasubramanian N, Fox-Geiman M, Smith SE, Parada JP. Evaluation of risk factors for Clostridium difficile infection in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2017;37(4):420\u20138. https:\/\/doi.org\/10.1002\/phar.1914.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1455_CR67","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1097\/TXD.0000000000000662","volume":"3","author":"ER Dubberke","year":"2017","unstructured":"Dubberke ER, Reske KA, Olsen MA, Bommarito KM, Seiler S, Silveira FP, et al. Risk for Clostridium difficile infection after allogeneic hematopoietic cell transplant remains elevated in the postengraftment period. Transplant Direct. 2017;3(4):e145. https:\/\/doi.org\/10.1097\/TXD.0000000000000662.","journal-title":"Transplant Direct"},{"issue":"Suppl 2","key":"1455_CR68","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/cid\/cis338","volume":"55","author":"TJ Louie","year":"2012","unstructured":"Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(Suppl 2):S132\u201342. https:\/\/doi.org\/10.1093\/cid\/cis338.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1455_CR69","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/cid\/ciy484","volume":"68","author":"KM Mullane","year":"2019","unstructured":"Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, et al. A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2019;68(2):196\u2013203. https:\/\/doi.org\/10.1093\/cid\/ciy484.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1455_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124483","volume":"10","author":"S Paudel","year":"2015","unstructured":"Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS ONE. 2015;10(4):e0124483. https:\/\/doi.org\/10.1371\/journal.pone.0124483.","journal-title":"PLoS ONE"},{"issue":"12","key":"1455_CR71","doi-asserted-by":"publisher","first-page":"e2141089","DOI":"10.1001\/jamanetworkopen.2021.41089","volume":"4","author":"SM Hosseini-Moghaddam","year":"2021","unstructured":"Hosseini-Moghaddam SM, Luo B, Bota SE, Husain S, Silverman MS, Daneman N, et al. Incidence and outcomes associated with Clostridioides difficile infection in solid organ transplant recipients. JAMA Netw Open. 2021;4(12):e2141089. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.41089.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1455_CR72","doi-asserted-by":"publisher","first-page":"ofz086","DOI":"10.1093\/ofid\/ofz086","volume":"6","author":"EE Ilett","year":"2019","unstructured":"Ilett EE, Helleberg M, Reekie J, Murray DD, Wulff SM, Khurana MP, et al. Incidence rates and risk factors of Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients. Open Forum Infect Dis. 2019;6(4):ofz086. https:\/\/doi.org\/10.1093\/ofid\/ofz086.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1455_CR73","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1017\/ice.2018.48","volume":"39","author":"R Luo","year":"2018","unstructured":"Luo R, Weinberg JM, Barlam TF. The impact of Clostridium difficile infection on future outcomes of solid organ transplant recipients. Infect Control Hosp Epidemiol. 2018;39(5):563\u201370. https:\/\/doi.org\/10.1017\/ice.2018.48.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"1455_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13459","volume":"23","author":"R Mahatanan","year":"2021","unstructured":"Mahatanan R, Tantisattamo E, Charoenpong P, Ferrey A. Outcomes of C difficile infection in solid-organ transplant recipients: the National Inpatient Sample (NIS) 2015\u20132016. Transpl Infect Dis. 2021;23(1):e13459. https:\/\/doi.org\/10.1111\/tid.13459.","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"1455_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13564","volume":"33","author":"KM Mullane","year":"2019","unstructured":"Mullane KM, Dubberke ER, Practice AICo. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation Community of Practice. Clin Transplant. 2019;33(9):e13564. https:\/\/doi.org\/10.1111\/ctr.13564.","journal-title":"Clin Transplant"},{"issue":"2","key":"1455_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12855","volume":"20","author":"ER Dubberke","year":"2018","unstructured":"Dubberke ER, Reske KA, Olsen MA, Bommarito K, Cleveland AA, Silveira FP, et al. Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients. Transpl Infect Dis. 2018;20(2):e12855. https:\/\/doi.org\/10.1111\/tid.12855.","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"1455_CR77","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/ajt.13491","volume":"15","author":"JP Donnelly","year":"2015","unstructured":"Donnelly JP, Wang HE, Locke JE, Mannon RB, Safford MM, Baddley JW. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant. 2015;15(11):2970\u20137. https:\/\/doi.org\/10.1111\/ajt.13491.","journal-title":"Am J Transplant"},{"key":"1455_CR78","doi-asserted-by":"publisher","first-page":"204993612110367","DOI":"10.1177\/20499361211036773","volume":"8","author":"AG Stewart","year":"2021","unstructured":"Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis. 2021;8:20499361211036772. https:\/\/doi.org\/10.1177\/20499361211036773.","journal-title":"Ther Adv Infect Dis"},{"key":"1455_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104134","volume":"192","author":"GK Reynolds","year":"2023","unstructured":"Reynolds GK, Sim B, Spelman T, Thomas A, Longhitano A, Anderson MA, et al. Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2023;192:104134. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104134.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1455_CR80","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ejh.14122","volume":"112","author":"N Garcia-Pouton","year":"2024","unstructured":"Garcia-Pouton N, Ortiz-Maldonado V, Peyrony O, Chumbita M, Aiello TF, Monzo-Gallo P, et al. Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy. Eur J Haematol. 2024;112(3):371\u20138. https:\/\/doi.org\/10.1111\/ejh.14122.","journal-title":"Eur J Haematol"},{"issue":"2","key":"1455_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.46989\/001c.115932","volume":"6","author":"N Ahmed","year":"2024","unstructured":"Ahmed N, Oluwole O, Mahmoudjafari Z, Suleman N, McGuirk JP. Managing infection complications in the setting of chimeric antigen receptor T cell (CAR-T) therapy. Clin Hematol Int. 2024;6(2):31\u201345. https:\/\/doi.org\/10.46989\/001c.115932.","journal-title":"Clin Hematol Int."},{"issue":"8","key":"1455_CR82","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925\u201335. https:\/\/doi.org\/10.1182\/blood.2019004000.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1455_CR83","doi-asserted-by":"publisher","first-page":"ofad500.121","DOI":"10.1093\/ofid\/ofad500.121","volume":"10","author":"VC Keri","year":"2023","unstructured":"Keri VC, Ramakrishna JM, Vyas R, Monday LM, Deol A, Chandrasekar P. Infections following chimeric antigen receptor (CAR)\u2014T cell therapy: 2018\u20132022. Open Forum Infect Dis. 2023;10(Suppl 2):ofad500.121. https:\/\/doi.org\/10.1093\/ofid\/ofad500.121","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"1455_CR84","doi-asserted-by":"publisher","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","volume":"28","author":"SJ Keating","year":"2022","unstructured":"Keating SJ, Gu T, Jun MP, McBride A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022;28(7):404.e1-e6. https:\/\/doi.org\/10.1016\/j.jtct.2022.03.021.","journal-title":"Transplant Cell Ther."},{"issue":"24","key":"1455_CR85","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMc1505190","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, Winston LG, McDonald LC. Emerging infections program C. difficile surveillance team. Burden of clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369\u201370. https:\/\/doi.org\/10.1056\/NEJMc1505190.","journal-title":"N Engl J Med"},{"issue":"1","key":"1455_CR86","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1080\/07853890.2022.2092893","volume":"54","author":"SO Park","year":"2022","unstructured":"Park SO, Yeo I. Trends in Clostridioides difficile prevalence, mortality, severity, and age composition during 2003\u20132014, the national inpatient sample database in the US. Ann Med. 2022;54(1):1851\u20138. https:\/\/doi.org\/10.1080\/07853890.2022.2092893.","journal-title":"Ann Med"},{"issue":"10","key":"1455_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009316","volume":"5","author":"A Ticinesi","year":"2015","unstructured":"Ticinesi A, Nouvenne A, Folesani G, Prati B, Morelli I, Guida L, et al. Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: a retrospective study with the Cumulative Illness Rating Scale (CIRS). BMJ Open. 2015;5(10):e009316. https:\/\/doi.org\/10.1136\/bmjopen-2015-009316.","journal-title":"BMJ Open"},{"issue":"1","key":"1455_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102499","volume":"49","author":"A Jaan","year":"2025","unstructured":"Jaan A, Farooq U, Alayoub AA, Nadeem H, Zahid E, Dhawan A, et al. Superiority of frailty over age in predicting outcomes among Clostridium difficile patients: evidence from national data. Clin Res Hepatol Gastroenterol. 2025;49(1):102499. https:\/\/doi.org\/10.1016\/j.clinre.2024.102499.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"1455_CR89","doi-asserted-by":"publisher","first-page":"ofy160","DOI":"10.1093\/ofid\/ofy160","volume":"5","author":"MA Olsen","year":"2018","unstructured":"Olsen MA, Stwalley D, Demont C, Dubberke ER. Increasing age has limited impact on risk of Clostridium difficile infection in an elderly population. Open Forum Infect Dis. 2018;5(7):ofy160. https:\/\/doi.org\/10.1093\/ofid\/ofy160.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1455_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01432-9","volume":"28","author":"MJ Fernandez-Cotarelo","year":"2023","unstructured":"Fernandez-Cotarelo MJ, Jackson-Akers JY, Nagy-Agren SE, Warren CA. Interaction of Clostridioides difficile infection with frailty and cognition in the elderly: a narrative review. Eur J Med Res. 2023;28(1):439. https:\/\/doi.org\/10.1186\/s40001-023-01432-9.","journal-title":"Eur J Med Res"},{"issue":"12","key":"1455_CR91","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.ajic.2024.08.020","volume":"52","author":"KR Reveles","year":"2024","unstructured":"Reveles KR, Strey KA, Albuquerque EL, Jacota D, Jones X, Carreno JJ. Retrospective, propensity score\u2013matched study examining the relationship between frailty and Clostridioides difficile infection in a national cohort of US veterans. Am J Infect Control. 2024;52(12):1412\u20138. https:\/\/doi.org\/10.1016\/j.ajic.2024.08.020.","journal-title":"Am J Infect Control"},{"issue":"1","key":"1455_CR92","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12879-016-2027-8","volume":"16","author":"A Pechal","year":"2016","unstructured":"Pechal A, Lin K, Allen S, Reveles K. National age group trends in Clostridium difficile infection incidence and health outcomes in United States community hospitals. BMC Infect Dis. 2016;16(1):682. https:\/\/doi.org\/10.1186\/s12879-016-2027-8.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1455_CR93","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s41999-023-00772-3","volume":"14","author":"T Rubak","year":"2023","unstructured":"Rubak T, Baunwall SMD, Gregersen M, Hansen TK, Rosenbaek JB, Erikstrup LT, et al. Frailty level at discharge predicts mortality in older patients with Clostridioides difficile more accurately than age or disease severity. Eur Geriatr Med. 2023;14(3):583\u201393. https:\/\/doi.org\/10.1007\/s41999-023-00772-3.","journal-title":"Eur Geriatr Med"},{"issue":"10","key":"1455_CR94","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/ggi.12866","volume":"17","author":"Y Leibovici-Weissman","year":"2017","unstructured":"Leibovici-Weissman Y, Atamna A, Schlesinger A, Eliakim-Raz N, Bishara J, Yahav D. Risk factors for short- and long-term mortality in very old patients with Clostridium difficile infection: a retrospective study. Geriatr Gerontol Int. 2017;17(10):1378\u201383. https:\/\/doi.org\/10.1111\/ggi.12866.","journal-title":"Geriatr Gerontol Int"},{"issue":"11","key":"1455_CR95","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.mayocp.2012.05.025","volume":"87","author":"MT Keddis","year":"2012","unstructured":"Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87(11):1046\u201353. https:\/\/doi.org\/10.1016\/j.mayocp.2012.05.025.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1455_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12010037","volume":"12","author":"A Alamri","year":"2024","unstructured":"Alamri A, Bin Abbas A, Al Hassan E, Almogbel Y. Development of a prediction model to identify the risk of Clostridioides difficile infection in hospitalized patients receiving at least one dose of antibiotics. Pharmacy (Basel). 2024;12(1):37. https:\/\/doi.org\/10.3390\/pharmacy12010037.","journal-title":"Pharmacy (Basel)"},{"issue":"5","key":"1455_CR97","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40121-023-00800-6","volume":"12","author":"T Weinke","year":"2023","unstructured":"Weinke T, Beier D, Brestrich G, von Eiff C, Hackl D, Heinrich K, et al. Epidemiology and risk factors of Clostridioides difficile infections in Germany: a health claims data analysis. Infect Dis Ther. 2023;12(5):1299\u2013317. https:\/\/doi.org\/10.1007\/s40121-023-00800-6.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"1455_CR98","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/antibiotics11060785","volume":"11","author":"L Lis","year":"2022","unstructured":"Lis L, Konieczny A, Sroka M, Ciszewska A, Krakowska K, Golebiowski T, et al. Clinical determinants predicting Clostridioides difficile infection among patients with chronic kidney disease. Antibiotics (Basel). 2022;11(6):785. https:\/\/doi.org\/10.3390\/antibiotics11060785.","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"1455_CR99","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.eimce.2021.04.008","volume":"40","author":"A Asensio","year":"2012","unstructured":"Asensio A, Vallejo-Plaza A, Parra LM, Orti-Lucas R, Salcedo I, Ramos A, et al. Epidemiology of Clostridioides difficile infection in hospitalized patients in Spain: an eight-year review (2012-2019). Enfermedades infecciosas y microbiologia clinica (English ed). 2012;40(3):125\u201330. https:\/\/doi.org\/10.1016\/j.eimce.2021.04.008.","journal-title":"Enfermedades infecciosas y microbiologia clinica (English ed)"},{"issue":"1","key":"1455_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000090","volume":"2","author":"WC Mutai","year":"2022","unstructured":"Mutai WC, Mureithi M, Anzala O, Kullin B, Ofwete R, Kyany AC, et al. Assessment of independent comorbidities and comorbidity measures in predicting healthcare facility-onset Clostridioides difficile infection in Kenya. PLOS Glob Public Health. 2022;2(1):e0000090. https:\/\/doi.org\/10.1371\/journal.pgph.0000090.","journal-title":"PLOS Glob Public Health"},{"issue":"6","key":"1455_CR101","first-page":"931","volume":"81","author":"L Jorge","year":"2021","unstructured":"Jorge L, Azula N, Smayevsky J, Herrera F, Temporiti E, Bonvehi P. Incidence, clinical characteristic and evolution of Clostridioides difficile infection [in Spanish]. Medicina (B Aires). 2021;81(6):931\u20138.","journal-title":"Medicina (B Aires)"},{"issue":"2","key":"1455_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020196","volume":"10","author":"S Dudzicz","year":"2021","unstructured":"Dudzicz S, Wiecek A, Adamczak M. Clostridioides difficile infection in chronic kidney disease\u2014an overview for clinicians. J Clin Med. 2021;10(2):196. https:\/\/doi.org\/10.3390\/jcm10020196.","journal-title":"J Clin Med"},{"issue":"7","key":"1455_CR103","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1017\/ice.2022.217","volume":"44","author":"YM Elfanagely","year":"2023","unstructured":"Elfanagely YM, Tanzer JR, Shobayo A, Mohamed MFH, Ho JJC, Shemin D, et al. Prevalence and trends of Clostridioides difficile infection among persons requiring maintenance hemodialysis: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2023;44(7):1068\u201375. https:\/\/doi.org\/10.1017\/ice.2022.217.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"1455_CR104","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jim-2016-000183","volume":"65","author":"A Tirath","year":"2017","unstructured":"Tirath A, Tadros S, Coffin SL, Kintziger KW, Waller JL, Baer SL, et al. Clostridium difficile infection in dialysis patients. J Investig Med. 2017;65(2):353\u20137. https:\/\/doi.org\/10.1136\/jim-2016-000183.","journal-title":"J Investig Med"},{"issue":"4","key":"1455_CR105","doi-asserted-by":"publisher","first-page":"ofz171","DOI":"10.1093\/ofid\/ofx171","volume":"4","author":"AY Guh","year":"2017","unstructured":"Guh AY, Adkins SH, Li Q, Bulens SN, Farley MM, Smith Z, et al. Risk factors for community-associated Clostridium difficile infection in adults: a case-control study. Open Forum Infect Dis. 2017;4(4):ofz171. https:\/\/doi.org\/10.1093\/ofid\/ofx171.","journal-title":"Open Forum Infect Dis"},{"key":"1455_CR106","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijid.2017.06.013","volume":"62","author":"A Goyal","year":"2017","unstructured":"Goyal A, Chatterjee K, Yadlapati S, Rangaswami J. Impact of end stage kidney disease on costs and outcomes of Clostridium difficile infection. Int J Infect Dis. 2017;62:8\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2017.06.013.","journal-title":"Int J Infect Dis"},{"key":"1455_CR107","doi-asserted-by":"publisher","unstructured":"Collaborators GBDCKD. Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10518):2461\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(25)01853-7.","DOI":"10.1016\/S0140-6736(25)01853-7"},{"issue":"2","key":"1455_CR108","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cgh.2016.10.024","volume":"15","author":"S Khanna","year":"2017","unstructured":"Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017;15(2):166\u201374. https:\/\/doi.org\/10.1016\/j.cgh.2016.10.024.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1455_CR109","doi-asserted-by":"publisher","first-page":"175628482110202","DOI":"10.1177\/17562848211020285","volume":"14","author":"K Sehgal","year":"2021","unstructured":"Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol. 2021;14:17562848211020284. https:\/\/doi.org\/10.1177\/17562848211020285.","journal-title":"Therap Adv Gastroenterol"},{"key":"1455_CR110","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251318292","volume":"18","author":"K Vitikainen","year":"2025","unstructured":"Vitikainen K, Kase M, Meriranta L, Molander P, Af Bjorkesten CG, Anttila VJ, et al. Higher disease activity of inflammatory bowel disease predisposes to Clostridioides difficile infection. Ther Adv Gastroenterol. 2025;18:17562848251318292. https:\/\/doi.org\/10.1177\/17562848251318292.","journal-title":"Ther Adv Gastroenterol"},{"issue":"2","key":"1455_CR111","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf024","volume":"7","author":"D Amakye","year":"2025","unstructured":"Amakye D, Ssentongo P, Patel S, Dalessio S, Kochhar S, Momin A, et al. Global patterns of Clostridioides difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of prevalence, epidemiology, and risk factors. Crohn\u2019s Colitis 360. 2025;7(2):otaf024. https:\/\/doi.org\/10.1093\/crocol\/otaf024.","journal-title":"Crohn's Colitis 360"},{"key":"1455_CR112","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002323","author":"S Duggal","year":"2025","unstructured":"Duggal S, Khattar S, Kattamuri L, Batheja M, Zuckerman MJ, Elhanafi SE. Impact of Clostridioides difficile infection on clinical outcomes in hospitalized patients with inflammatory bowel disease: a nationwide analysis. J Clin Gastroenterol Epub. 2025. https:\/\/doi.org\/10.1097\/MCG.0000000000002323.","journal-title":"J Clin Gastroenterol Epub"},{"issue":"8","key":"1455_CR113","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/ibd\/izy086","volume":"24","author":"GE Barber","year":"2018","unstructured":"Barber GE, Hendler S, Okafor P, Limsui D, Limketkai BN. Rising incidence of intestinal infections in inflammatory bowel disease: a nationwide analysis. Inflamm Bowel Dis. 2018;24(8):1849\u201356. https:\/\/doi.org\/10.1093\/ibd\/izy086.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"1455_CR114","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/MEG.0000000000001185","volume":"30","author":"M Rezapour","year":"2018","unstructured":"Rezapour M, Galoosian A, Liu B, Bhuket T, Wong RJ. Clostridium difficile co-infection in inflammatory bowel disease is associated with significantly increased in-hospital mortality. Eur J Gastroenterol Hepatol. 2018;30(9):1041\u20136. https:\/\/doi.org\/10.1097\/MEG.0000000000001185.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"1455_CR115","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/apt.17777","volume":"59","author":"EJ Spartz","year":"2024","unstructured":"Spartz EJ, DeDecker LC, Fansiwala KM, Noorian S, Roney AR, Hakimian S, et al. Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59(1):89\u201399. https:\/\/doi.org\/10.1111\/apt.17777.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1455_CR116","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjy143","volume":"13","author":"B Balram","year":"2019","unstructured":"Balram B, Battat R, Al-Khoury A, D\u2019Aoust J, Afif W, Bitton A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019;13(1):27\u201338. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy143.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"1455_CR117","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43134","volume":"15","author":"L Sangurima","year":"2023","unstructured":"Sangurima L, Malik MM, Ganatra N, Siby R, Kumar S, Khan S, et al. Clostridioides difficile infection in inflammatory bowel disease patients: a systematic review of risk factors and approach in management. Cureus. 2023;15(8):e43134. https:\/\/doi.org\/10.7759\/cureus.43134.","journal-title":"Cureus"},{"issue":"3","key":"1455_CR118","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5114\/pg.2024.143145","volume":"19","author":"A Jakubowska","year":"2024","unstructured":"Jakubowska A, Szydlarska D, Rydzewska G. Analysis of risk factors of Clostridioides difficile infection in patients with inflammatory bowel disease. Prz Gastroenterol. 2024;19(3):277\u201383. https:\/\/doi.org\/10.5114\/pg.2024.143145.","journal-title":"Prz Gastroenterol"},{"key":"1455_CR119","doi-asserted-by":"publisher","DOI":"10.1177\/1756284821997792","volume":"14","author":"E Voth","year":"2021","unstructured":"Voth E, Solanky D, Loftus EV Jr., Pardi DS, Khanna S. Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection. Therap Adv Gastroenterol. 2021;14:1756284821997792. https:\/\/doi.org\/10.1177\/1756284821997792.","journal-title":"Therap Adv Gastroenterol"},{"issue":"11","key":"1455_CR120","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1097\/MIB.0000000000000939","volume":"22","author":"JD McCurdy","year":"2016","unstructured":"McCurdy JD, Enders FT, Khanna S, Bruining DH, Jones A, Killian JM, et al. Increased rates of Clostridium difficile infection and poor outcomes in patients with IBD with cytomegalovirus. Inflamm Bowel Dis. 2016;22(11):2688\u201393. https:\/\/doi.org\/10.1097\/MIB.0000000000000939.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"1455_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112702","volume":"13","author":"C Seguiti","year":"2025","unstructured":"Seguiti C, Tettoni E, Pezzuto E, Gerardi V, Quadarella A, Cesaro P, et al. Clostridioides difficile infection in special populations: focus on inflammatory bowel disease-a narrative review from pathogenesis to management. Biomedicines. 2025;13(11):2702. https:\/\/doi.org\/10.3390\/biomedicines13112702.","journal-title":"Biomedicines"},{"issue":"2","key":"1455_CR122","doi-asserted-by":"publisher","first-page":"313","DOI":"10.14309\/ajg.0000000000003076","volume":"120","author":"BP Vaughn","year":"2025","unstructured":"Vaughn BP, Khoruts A, Fischer M. Diagnosis and management of Clostridioides difficile in inflammatory bowel disease. Am J Gastroenterol. 2025;120(2):313\u20139. https:\/\/doi.org\/10.14309\/ajg.0000000000003076.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"1455_CR123","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1097\/MIB.0000000000001251","volume":"23","author":"A Anderson","year":"2017","unstructured":"Anderson A, Click B, Ramos-Rivers C, Cheng D, Babichenko D, Koutroubakis IE, et al. Lasting impact of Clostridium difficile infection in inflammatory bowel disease: a propensity score matched analysis. Inflamm Bowel Dis. 2017;23(12):2180\u20138. https:\/\/doi.org\/10.1097\/MIB.0000000000001251.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"1455_CR124","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/MIB.0000000000001218","volume":"23","author":"S Bhandari","year":"2017","unstructured":"Bhandari S, Mohammed Abdul MK, Dhakal B, Kreuziger LB, Saeian K, Stein D. Increased rate of venous thromboembolism in hospitalized inflammatory bowel disease patients with Clostridium difficile infection. Inflamm Bowel Dis. 2017;23(10):1847\u201352. https:\/\/doi.org\/10.1097\/MIB.0000000000001218.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1455_CR125","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MOG.0000000000000949","volume":"39","author":"T Alhobayb","year":"2023","unstructured":"Alhobayb T, Ciorba MA. Clostridium difficile in inflammatory bowel disease. Curr Opin Gastroenterol. 2023;39(4):257\u201362. https:\/\/doi.org\/10.1097\/MOG.0000000000000949.","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"1455_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146822","volume":"11","author":"ER Dubberke","year":"2016","unstructured":"Dubberke ER, Olsen MA, Stwalley D, Kelly CP, Gerding DN, Young-Xu Y, et al. Identification of Medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis. PLoS ONE. 2016;11(2):e0146822. https:\/\/doi.org\/10.1371\/journal.pone.0146822.","journal-title":"PLoS ONE"},{"issue":"2","key":"1455_CR127","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40121-024-00919-0","volume":"13","author":"J Eeuwijk","year":"2024","unstructured":"Eeuwijk J, Ferreira G, Yarzabal JP, Robert-Du Ry van Beest Holle M. A systematic literature review on risk factors for and timing of Clostridioides difficile infection in the United States. Infect Dis Ther. 2024;13(2):273\u201398. https:\/\/doi.org\/10.1007\/s40121-024-00919-0.","journal-title":"Infect Dis Ther"},{"issue":"8","key":"1455_CR128","doi-asserted-by":"publisher","first-page":"926","DOI":"10.4254\/wjh.v13.i8.926","volume":"13","author":"S Sahra","year":"2021","unstructured":"Sahra S, Abureesh M, Amarnath S, Alkhayyat M, Badran R, Jahangir A, et al. Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States. World J Hepatol. 2021;13(8):926\u201338. https:\/\/doi.org\/10.4254\/wjh.v13.i8.926.","journal-title":"World J Hepatol"},{"issue":"12","key":"1455_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209152","volume":"13","author":"TF Barlam","year":"2018","unstructured":"Barlam TF, Soria-Saucedo R, Ameli O, Cabral HJ, Kaplan WA, Kazis LE. Retrospective analysis of long-term gastrointestinal symptoms after Clostridium difficile infection in a nonelderly cohort. PLoS ONE. 2018;13(12):e0209152. https:\/\/doi.org\/10.1371\/journal.pone.0209152.","journal-title":"PLoS ONE"},{"key":"1455_CR130","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PPA.S229539","volume":"14","author":"J Vent-Schmidt","year":"2020","unstructured":"Vent-Schmidt J, Attara GP, Lisko D, Steiner TS. Patient experiences with Clostridioides difficile infection: results of a canada-wide survey. Patient Prefer Adherence. 2020;14:33\u201343. https:\/\/doi.org\/10.2147\/PPA.S229539.","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"1455_CR131","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1017\/ice.2023.37","volume":"44","author":"KA Reagan","year":"2023","unstructured":"Reagan KA, Chan DM, Vanhoozer G, Bearman G. Estimating the effect of active detection and isolation on Clostridioides difficile infections in a bone marrow transplant unit. Infect Control Hosp Epidemiol. 2023;44(10):1614\u20139. https:\/\/doi.org\/10.1017\/ice.2023.37.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"1455_CR132","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/cid\/ciy425","volume":"67","author":"B Paquet-Bolduc","year":"2018","unstructured":"Paquet-Bolduc B, Gervais P, Roussy JF, Trottier S, Oughton M, Brukner I, et al. Detection and isolation of Clostridium difficile asymptomatic carriers during Clostridium difficile infection outbreaks: an exploratory study. Clin Infect Dis. 2018;67(11):1781\u20133. https:\/\/doi.org\/10.1093\/cid\/ciy425.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1455_CR133","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030371","volume":"10","author":"E Purssell","year":"2020","unstructured":"Purssell E, Gould D, Chudleigh J. Impact of isolation on hospitalised patients who are infectious: systematic review with meta-analysis. BMJ Open. 2020;10(2):e030371. https:\/\/doi.org\/10.1136\/bmjopen-2019-030371.","journal-title":"BMJ Open"},{"issue":"2","key":"1455_CR134","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jhin.2010.04.027","volume":"76","author":"C Abad","year":"2010","unstructured":"Abad C, Fearday A, Safdar N. Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect. 2010;76(2):97\u2013102. https:\/\/doi.org\/10.1016\/j.jhin.2010.04.027.","journal-title":"J Hosp Infect"},{"issue":"9","key":"1455_CR135","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajic.2019.12.023","volume":"48","author":"F Morgan","year":"2020","unstructured":"Morgan F, Belal M, Lisa B, Ford F, LeMaitre B, Psevdos G. Antimicrobial stewardship program achieved marked decrease in Clostridium difficile infections in a Veterans Hospital. Am J Infect Control. 2020;48(9):1119\u201321. https:\/\/doi.org\/10.1016\/j.ajic.2019.12.023.","journal-title":"Am J Infect Control"},{"issue":"2","key":"1455_CR136","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/antibiotics15020112","volume":"15","author":"JH Park","year":"2026","unstructured":"Park JH, Kim J, Lee J, Chung H, Kim MC. Effects of antibiotic stewardship program on antibiotic consumption and the incidence of Clostridioides difficile infection. Antibiotics. 2026;15(2):112. https:\/\/doi.org\/10.3390\/antibiotics15020112.","journal-title":"Antibiotics"},{"issue":"6","key":"1455_CR137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234031","volume":"15","author":"S Rhea","year":"2020","unstructured":"Rhea S, Jones K, Endres-Dighe S, Munoz B, Weber DJ, Hilscher R, et al. Modeling inpatient and outpatient antibiotic stewardship interventions to reduce the burden of Clostridioides difficile infection in a regional healthcare network. PLoS ONE. 2020;15(6):e0234031. https:\/\/doi.org\/10.1371\/journal.pone.0234031.","journal-title":"PLoS ONE"},{"issue":"8","key":"1455_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081027","volume":"11","author":"E Liu","year":"2022","unstructured":"Liu E, Linder KE, Kuti JL. Antimicrobial stewardship at transitions of care to outpatient settings: synopsis and strategies. Antibiotics (Basel). 2022;11(8):1027. https:\/\/doi.org\/10.3390\/antibiotics11081027.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"1455_CR139","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2022.53","volume":"2","author":"M So","year":"2022","unstructured":"So M, Tsai H, Swaminathan N, Bartash R. Bring it on: top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e72. https:\/\/doi.org\/10.1017\/ash.2022.53.","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"issue":"4","key":"1455_CR140","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.idc.2025.07.015","volume":"39","author":"K Rao","year":"2025","unstructured":"Rao K, Wiens J. Predictive modeling for clostridioides difficile infection: current state of the science, clinical applications, and future directions. Infect Dis Clin North Am. 2025;39(4):743\u201359. https:\/\/doi.org\/10.1016\/j.idc.2025.07.015.","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"1455_CR141","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15213","volume":"8","author":"S Tang","year":"2025","unstructured":"Tang S, Shepard S, Clark R, Otles E, Udegbunam C, Tran J, et al. Guiding Clostridioides difficile Infection Prevention Efforts in a Hospital Setting With AI. JAMA Netw Open. 2025;8(6):e2515213. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15213.","journal-title":"JAMA Netw Open"},{"key":"1455_CR142","unstructured":"ClinicalTrials.gov. NCT05805826. To understand the safety and effects of a C. difficile vaccine with new adds-ons that will be given to healthy adults. https:\/\/clinicaltrials.gov\/study\/NCT05805826. Accessed August 2026."},{"key":"1455_CR143","unstructured":"ClinicalTrials.gov. NCT07285213. Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody (PRISM). https:\/\/clinicaltrials.gov\/study\/NCT007285213. Accessed August 2026."},{"key":"1455_CR144","unstructured":"ClinicalTrials.gov. NCT06237452. VE303 for Prevention of Recurrent Clostridioides Difficile Infection (RESTORATiVE303). https:\/\/clinicaltrials.gov\/study\/NCT06237452. Accessed August 2026."},{"issue":"6","key":"1455_CR145","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","volume":"116","author":"CR Kelly","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124\u201347. https:\/\/doi.org\/10.14309\/ajg.0000000000001278.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1455_CR146","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/nu10111574","volume":"10","author":"S Dudzicz","year":"2018","unstructured":"Dudzicz S, Kujawa-Szewieczek A, Kwiecien K, Wiecek A, Adamczak M. Lactobacillus plantarum 299v reduces the incidence of Clostridium difficile infection in nephrology and transplantation ward\u2014results of one year extended study. Nutrients. 2018;10(11):1574. https:\/\/doi.org\/10.3390\/nu10111574.","journal-title":"Nutrients"},{"key":"1455_CR147","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5466656","volume":"2021","author":"A Mihaescu","year":"2021","unstructured":"Mihaescu A, Augustine AM, Khokhar HT, Zafran M, Masood S, Gilca-Blanariu GE, et al. Clostridioides difficile infection in patients with chronic kidney disease: a systematic review. BioMed Res Int. 2021;2021:5466656. https:\/\/doi.org\/10.1155\/2021\/5466656.","journal-title":"BioMed Res Int"},{"issue":"15","key":"1455_CR148","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.3390\/jcm11154365","volume":"11","author":"S Dudzicz-Gojowy","year":"2022","unstructured":"Dudzicz-Gojowy S, Wiecek A, Adamczak M. Clostridioides difficile infection in patients after organ transplantation-a narrative overview. J Clin Med. 2022;11(15):4365. https:\/\/doi.org\/10.3390\/jcm11154365.","journal-title":"J Clin Med"},{"issue":"5","key":"1455_CR149","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3201\/eid2905.221618","volume":"29","author":"JA Ramirez","year":"2019","unstructured":"Ramirez JA, Angulo FJ, Carrico RM, Furmanek S, Oliva SP, Zamparo JM, et al. Misdiagnosis of Clostridioides difficile infections by standard-of-care specimen collection and testing among hospitalized adults, Louisville, Kentucky, USA, 2019-2020. Emerg Infect Dis. 2019;29(5):919\u201328. https:\/\/doi.org\/10.3201\/eid2905.221618.","journal-title":"Emerg Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01455-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:53:45Z","timestamp":1792029225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01455-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":149,"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01455-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jessica R. Allegretti reports consulting fees from Janssen, Pfizer, AbbVie, Vedanta, Genentech, Seres Therapeutics, Ferring, GSK, Merck, Bristol Myers Squibb Roivant, Celltrion, TRex Bio, Xencor, Shattuck Labs, Metagen, Curogen, Klear Bio, RESTEM, Spyre, and SEED; and payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from AbbVie and Janssen. Erik R. Dubberke reports grants or contracts to their institution from AstraZeneca, Pfizer, Theriva Biologics, and Vedanta Bioscience; and consulting fees from AstraZeneca, Pfizer, Vedanta Bioscience, GSK, and Idorsia. C\u00e1tia Ferreira was an employee of, and may hold stocks in, AstraZeneca. Christian John Lillis reports payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from AstraZeneca and Cepheid; and is the co-founder and CEO of the Peggy Lillis Foundation and a Trustee of the\n                      C. Diff\n                      Trust. Mark H. Wilcox reports grants or contracts to their institution from AstraZeneca, Seres, and Tillotts; consulting fees from AstraZeneca, Ferring, Nestl\u00e9, Pfizer, Tillotts, and Vedanta; and payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from AstraZeneca, Seres, and Tillotts.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}